6-APB vs MDMA: Risks Compared

6-APB is often described as an MDMA-like drug, but it is a different substance with less research behind it. This guide compares the known health risks, warning signs and legal status of 6-APB and MDMA.

Scientist pipetting samples in a laboratory, illustrating research comparing 6-APB and MDMA risks

Educational content. This article does not provide dosing, sourcing or buying information. It explains health risks so readers can make safer decisions and recognise when someone needs help.

6-APB (sometimes sold as part of so-called ‘Benzofury’ products) is a benzofuran: a synthetic stimulant with effects that users and researchers often compare to MDMA. Because the two are discussed together so often, many people assume 6-APB is simply a milder or ‘legal’ version of ecstasy. It is not. This article compares what is known about both substances, where the risks overlap, and where 6-APB brings extra uncertainty.

What are 6-APB and MDMA?

MDMA (3,4-methylenedioxymethamphetamine) is an amphetamine derivative that has been studied for decades. It is the main ingredient intended to be in ecstasy pills and ‘molly’ powder, and it has also been researched in clinical trials for post-traumatic stress disorder under strict medical supervision.

6-APB (6-(2-aminopropyl)benzofuran) appeared on the recreational market around 2010 as a new psychoactive substance. It belongs to the benzofuran family together with 5-APB and 5-MAPB, which we cover in our overview of benzofurans and their dangers. It has never been tested in controlled human trials, so most of what is known comes from laboratory studies, poison-centre reports and user accounts.

How they affect the body

Both drugs act mainly on the brain’s serotonin, dopamine and noradrenaline systems. They cause the release of these chemical messengers and block their reuptake, which produces euphoria, increased sociability and stimulation, along with a rise in heart rate, blood pressure and body temperature.

Laboratory research suggests 6-APB is a more potent releaser at some of these sites than MDMA and that it also strongly activates the serotonin 5-HT2B receptor. This receptor is of interest to doctors because long-term activation of it has been linked to heart valve damage with some other medicines. Whether this causes problems in people who use 6-APB is not known, but it is one reason researchers are cautious.

6-APB vs MDMA: where the risks overlapShared risks• Overheating (hyperthermia)• Raised heart rate and blood pressure• Serotonin syndrome• Low blood sodiumExtra 6-APB concerns• Longer-lasting effects• Strong 5-HT2B activity• Almost no human research• Unknown purity and mislabelling
Both drugs share serious short-term risks; 6-APB adds uncertainty because it has barely been studied.

Reported side effects

Side effects reported for both substances include:

  • jaw clenching and teeth grinding
  • sweating, raised temperature and flushing
  • fast or pounding heartbeat
  • nausea and loss of appetite
  • anxiety, restlessness and insomnia
  • low mood in the days afterwards

With 6-APB, users and case reports frequently describe effects that last considerably longer than MDMA. A longer duration means a longer period of strain on the heart, more disrupted sleep and a greater temptation to take more before the first effects have worn off.

Main health risks compared

Overheating and dehydration

Both drugs raise body temperature. In hot, crowded environments with dancing, this can lead to dangerous hyperthermia, muscle breakdown and organ failure. Our guide to stimulant overdose and overheating explains these warning signs in more detail.

Low sodium (hyponatraemia)

MDMA causes the body to hold on to water. Combined with drinking large amounts, this can dilute blood sodium and cause brain swelling. Because 6-APB acts in similar ways, a comparable risk is assumed, though it is less well documented.

Heart and blood vessels

Raised heart rate and blood pressure are a risk with both drugs, especially for people with existing heart conditions. The 5-HT2B finding for 6-APB adds a theoretical long-term concern that also comes up with other designer stimulants, such as the aminorex analogues.

Mental health

Anxiety, panic, paranoia and, in rare cases, psychosis have been reported with both. Heavy or repeated use of MDMA is associated with low mood and memory problems; equivalent long-term data for 6-APB do not exist.

Unknown contents

Products sold as 6-APB have been found to contain other benzofurans, cathinones or mixtures. Ecstasy pills can also contain unexpected substances or far more MDMA than expected. In both cases, the label is not a guarantee.

Dangerous combinations

Combining either drug with the following is associated with serious harm:

  • Antidepressants (especially MAOIs, and also SSRIs and SNRIs) – risk of serotonin syndrome
  • Other stimulants (amphetamine, cocaine, cathinones) – greater strain on the heart and higher overheating risk
  • Tramadol – seizure and serotonin syndrome risk
  • Alcohol – adds to dehydration and impairs judgement
  • Another dose of a different MDMA-like drug – unpredictable, stacked effects

Emergency warning signs

  • very high temperature, hot dry skin or stopping sweating
  • confusion, agitation or hallucinations
  • muscle stiffness, twitching or jerking
  • chest pain or a racing, irregular heartbeat
  • seizures or collapse
  • severe headache, vomiting or drowsiness after drinking a lot of water

What to do

Call emergency services straight away: 112 in the EU, 999 in the UK or 911 in the US. Tell them what was taken if you know. Move the person somewhere cooler, loosen tight clothing and stay with them. If they are unconscious but breathing, place them in the recovery position. Do not leave them to ‘sleep it off’.

Legal status

  • Netherlands: MDMA is on List I of the Opium Act. Benzofurans have been brought under Dutch controls on new psychoactive substances; see our explainer on the Dutch ban.
  • UK: MDMA is Class A. 6-APB and related benzofurans are Class B under the Misuse of Drugs Act.
  • Germany: MDMA is controlled under the Narcotics Act (BtMG); benzofurans are controlled under German narcotics law or the NpSG.
  • US: MDMA is Schedule I. 6-APB is not separately scheduled federally but may be prosecuted as an analogue of a controlled substance.

This is a general summary, not legal advice, and laws change.

Getting help

  • Netherlands: Drugs Infolijn (Trimbos Institute); DIMS drug-checking service
  • UK: FRANK – 0300 123 6600
  • US: SAMHSA National Helpline – 1-800-662-4357

Related reading

FAQ

Is 6-APB safer than MDMA?

There is no evidence that it is. It shares MDMA’s main short-term dangers, lasts longer and has far less research behind it.

Can 6-APB cause serotonin syndrome?

Yes. Like MDMA, it releases serotonin, so the risk is highest when combined with antidepressants, tramadol or other serotonergic drugs.

Why do the effects of 6-APB last so long?

Its chemistry and the way the body processes it differ from MDMA. A long duration increases strain on the body and the risk of taking more too soon.

This article is for general information and is not medical advice. If you are worried about your own or someone else’s drug use, speak to a doctor or one of the services listed above.

Share on Twitter
✦ Written by
Research Chemicals Blog Editorial Team

The Research Chemicals Blog editorial team writes independent guides on laboratory chemicals, reagents and suppliers, and evidence-based drug-safety information drawn from public-health sources such as the EU Drugs Agency, WHO, NHS and NIDA. We never sell, recommend or link to sellers of psychoactive substances, and we never publish dosing or sourcing information.

ResearchChemicals.blog

© 2026 researchchemicals.blog · Independent guides for laboratory buyers. Not affiliated with any supplier named on this site.